Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027741 | 0.89 | KDR (0.67) | KDRMAPTKMT2A | |
| SCHEMBL4016130 | 0.87 | KDR (0.68) | KDRBLMKMT2AABL1EGFR | |
| SCHEMBL4020907 | 0.86 | KDR (0.64) | KDRMAPTKMT2AABL1EGFR | |
| SCHEMBL4017759 | 0.86 | KDR (0.70) | KDRKMT2AFLT1 | |
| SCHEMBL4021410 | 0.86 | KDR (0.70) | KDRBLMMAPTKMT2A | |
| SCHEMBL4017534 | 0.86 | KDR (0.64) | KDRKMT2AABL1EGFRCSF1R | |
| SCHEMBL4016693 | 0.84 | KDR (0.64) | KDRMAPTKMT2A | |
| SCHEMBL4024905 | 0.84 | KDR (0.61) | KDRMAPTKMT2A | |
| SCHEMBL4018538 | 0.83 | KDR (0.60) | KDRMAPTKMT2AAR | |
| SCHEMBL4016774 | 0.82 | KDR (0.76) | KDRKMT2AABL1EGFRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527326-B1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-1602647-B1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-1602647-B1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518973-B2 | Compounds having 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207194-B2 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534802-B2 | Compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1602647-A1 | NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194836-A1 | Novel compounds having 4-pyridylalkylthio group as substituent | FLT4, FLT1, KDR | KDR 3/4885BLM 3085/4885MAPT 4765/4885 |
| US-20090286786-A1 | Compounds having a 4-pyridylalkylthio group as a substituent | FLT1, FLT4, PYM1 | KDR 5/4885BLM 3479/4885MAPT 4866/4885 |
| US-20120202817-A1 | COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT | FLT1, PYM1, FLT4 | KDR 6/4885BLM 4101/4885MAPT 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.